Trial results show efficacy of netakimab for treating moderate-to-severe plaque psoriasis

Trial results show efficacy of netakimab for treating moderate-to-severe plaque psoriasis

Trial results show efficacy of netakimab for treating moderate-to-severe plaque psoriasis

Netakimab is a humanized anti-interleukin 17A antibody approved for the treatment of moderate-to-severe plaque psoriasis.